Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
MarketWatch on MSN12d
This Wegovy user spent $5,000 on a new wardrobe after losing 80 pounds — and she’s not aloneTori Allen says she’s thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more ...
Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...
Sales of weight loss drug Wegovy more than doubled in the final three months of 2024 but its manufacturer has predicted growth will slow this year. Novo Nordisk's rise to become one of Europe's ...
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback